A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma
Phase of Trial: Phase III
Latest Information Update: 15 Dec 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms RAMO-2
- Sponsors Archigen Biotech
- 09 Aug 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jul 2018.
- 09 Aug 2017 Status changed from not yet recruiting to recruiting.
- 30 Jun 2016 New trial record